Research Topics
| GILLIAN SANDERSSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritisAlex R Kemper
Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA
BMC Pediatr 12:29. 2012..g., non-steroidal anti-inflammatory drugs, intra-articular corticosteroids). The purpose of this systematic review was to evaluate the comparative effectiveness and safety of DMARDs versus conventional therapy and versus other DMARDs...
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapyGillian D Sanders
Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
N Engl J Med 352:570-85. 2005..The costs, benefits, and cost-effectiveness of screening for human immunodeficiency virus (HIV) in health care settings during the era of highly active antiretroviral therapy (HAART) have not been determined...- Cost-effectiveness of implantable cardioverter-defibrillatorsGillian D Sanders
Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
N Engl J Med 353:1471-80. 2005..We assessed the cost-effectiveness of the ICD in the populations represented in these primary-prevention trials... - Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policyGillian D Sanders
Duke Clinical Research Institute, Duke Medical Center, Durham, NC 27715, USA
Am Heart J 153:951-9. 2007.... 
Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of ageGillian D Sanders
Duke Clinical Research Institute, Duke University, Durham, NC, USA
Am Heart J 160:122-31. 2010..We sought to examine the cost-effectiveness of ICD therapy in at-risk patients >or=65 years old...- Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trialGillian D Sanders
Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
J Gen Intern Med 25:556-63. 2010..The CDC recommends routine voluntary HIV testing of all patients 13-64 years of age. Despite this recommendation, HIV testing rates are low even among those at identifiable risk, and many patients do not return to receive their results... - Cost-effectiveness of HIV screening in patients older than 55 years of ageGillian D Sanders
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
Ann Intern Med 148:889-903. 2008..Recent guidelines recommend HIV screening in patients age 13 to 64 years. The cost-effectiveness of HIV screening in patients age 55 to 75 years is uncertain... - Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trialsSana M Al-Khatib
Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
JAMA 309:55-62. 2013..Whether the survival of patients who received an ICD in primary prevention clinical trials differs from that of trial-eligible patients receiving a primary prevention ICD in clinical practice is unknown... - An economic evaluation of prolonged mechanical ventilationChristopher E Cox
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Duke University, Durham, NC, USA
Crit Care Med 35:1918-27. 2007..Therefore, we aimed to determine the lifetime societal value of prolonged mechanical ventilation... - Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac deathSana M Al-Khatib
The Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 153:941-50. 2007..This article summarizes the presentations and discussions that occurred at that meeting... - Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?Laura J Havrilesky
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 111:179-87. 2008..We wished to estimate the clinical impact and cost-effectiveness of potential screening strategies for ovarian cancer using population-specific data... - Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death preventionSana M Al-Khatib
The Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 156:613-22. 2008..Although the meeting was funded by industry participants, this article summarizing the presentations and discussions that occurred at the meeting presents the expert opinion of the authors... - Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trialSana M Al-Khatib
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
J Cardiovasc Electrophysiol 21:545-50. 2010..We sought to determine whether remote monitoring of ICDs improves patient outcomes compared with quarterly device interrogations in clinic... - Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapiesMelissa H Kong
Duke Clinical Research Institute, Durham, NC, USA
Am Heart J 160:605-18. 2010..This article summarizes the discussions that occurred at the meeting... - Non-evidence-based ICD implantations in the United StatesSana M Al-Khatib
Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
JAMA 305:43-9. 2011.... - Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reductionLaura J Havrilesky
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 117:545-53. 2011..The objective of the current study was to estimate the impact of a 2-phenotype paradigm of epithelial ovarian cancer on the mortality reduction achievable using available screening technologies... - Systematic review of the incidence of sudden cardiac death in the United StatesMelissa H Kong
Duke Clinical Research Institute, Durham, North Carolina, USA
J Am Coll Cardiol 57:794-801. 2011..S. population... - Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysisJonathan P Piccini
Duke Clinical Research Institute and the Duke University School of Medicine, Durham, North Carolina 27705, USA
J Cardiovasc Electrophysiol 21:791-8. 2010..The optimal timing of implantable cardioverter defibrillator (ICD) placement for the primary prevention of sudden cardiac death after myocardial infarction (MI) remains unknown... - Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004Sana M Al-Khatib
The Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 149:1020-34. 2005..This document summarizes the evidence reviewed at that meeting and the discussions of that evidence... - Do physicians' attitudes toward implantable cardioverter defibrillator therapy vary by patient age, gender, or race?Sana M Al-Khatib
Duke Cardiovascular Center for Education and Research on Therapeutics, Duke Clinical Research Institute, Durham, NC, USA
Ann Noninvasive Electrocardiol 16:77-84. 2011..We assessed whether physicians' recommendation for ICD therapy varies as a function of patient age, gender, race, and physician's specialty... - Extent of and reasons for nonuse of implantable cardioverter defibrillator devices in clinical practice among eligible patients with left ventricular systolic dysfunctionNancy M Allen LaPointe
Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27705, USA
Circ Cardiovasc Qual Outcomes 4:146-51. 2011..The extent and documented reasons for nonuse of ICDs among patients with left ventricular systolic dysfunction are unknown... - Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infectionDavid P Holland
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Am J Respir Crit Care Med 179:1055-60. 2009..Shorter course regimens and regimens using directly observed therapy result in improved adherence but have higher upfront costs... - Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosisAndrew D Auerbach
Department of Medicine, University of California, San Francisco, CA 94143 0131, USA
Am J Med 116:816-28. 2004..We sought to determine the cost-effectiveness of testing for these disorders, as well as which tests should be selected and how results should be used... - Cost-effectiveness of the implantable cardioverter defibrillatorMark A Hlatky
Department of Health Research and Policy, Stanford University School of Medicine, CA 94305 5405, USA
Card Electrophysiol Rev 7:479-82. 2003..A rough rule of thumb is that the ICD will be economically attractive when it prolongs mean survival by six months or more, which is attainable in higher risk patient subgroups... - Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodulesMichael K Gould
Pulmonary Section, Veterans Affairs Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, California 94304, USA
Ann Intern Med 138:724-35. 2003..Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) is a potentially useful but expensive test to diagnose solitary pulmonary nodules... - Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsisRobert A Fowler
Division of General Medicine and Critical Care Medicine, Department of Medicine, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario, Canada
J Crit Care 18:181-91; discussion 191-4. 2003..To evaluate the cost-effectiveness of recombinant human activated protein C (rhAPC) compared with usual therapy for patients with severe sepsis, and also to determine the influence that severity of illness exerts on cost-effectiveness... - Cost-effectiveness of a potential vaccine for human papillomavirusGillian D Sanders
Center for Primary Care and Outcomes Research, 117 Encina Commons, Stanford University, Stanford, CA 94305 6019, USA
Emerg Infect Dis 9:37-48. 2003..If the vaccine efficacy rate is 35%, the cost effectiveness increases to $52,398/QALY. Although gains in life expectancy may be modest at the individual level, population benefits are substantial... - Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillatorDouglas K Owens
VA Health Care System, Palo Alto, Calif 94304, USA
Am Heart J 144:440-8. 2002..We evaluated whether risk stratification based on risk of sudden cardiac death alone was sufficient to predict the effectiveness and cost-effectiveness of the ICD... - Perinatal screening for group B streptococci: cost-benefit analysis of rapid polymerase chain reactionCorinna A Haberland
Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, California 94305, USA
Pediatrics 110:471-80. 2002..To evaluate the costs and benefits of a group B streptococci screening strategy using a new, rapid polymerase chain reaction test in a hypothetical cohort of expectant mothers in the United States... - Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolismDaniella J Perlroth
Department of Medicine, School of Medicine, Stanford University, Stanford, California, USA
Arch Intern Med 167:74-80. 2007..Thrombolytic therapy is controversial in patients with submassive pulmonary embolism... - Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagusRohini Vij
Division of Gastroenterology and Hepatology, Center for Primary Care and Outcomes Research, Department of Medicine, Stanford University School of Medicine, California, USA
Gastrointest Endosc 60:739-56. 2004..Clinical trials directly comparing these strategies are warranted... - Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysisEran Bendavid
Center for Health Policy and the Center for Primary Care and Outcomes Research, School of Medicine, Stanford University, 117 Encina Commons, Stanford, CA 94305, USA
Arch Intern Med 168:1910-8. 2008..Although the number of infected persons receiving highly active antiretroviral therapy (HAART) in low- and middle-income countries has increased dramatically, optimal disease management is not well defined... - Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, RussiaElisa F Long
Department of Management Science and Engineering, Stanford University, Stanford, CA 94305, USA
AIDS 20:2207-15. 2006..To assess the effectiveness and cost-effectiveness of treating HIV-infected injection drug users (IDUs) and non-IDUs in Russia with highly active antiretroviral therapy HAART... - Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthraxRobert A Fowler
Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Ann Intern Med 142:601-10. 2005..Weaponized Bacillus anthracis is one of the few biological agents that can cause death and disease in sufficient numbers to devastate an urban setting... - Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIVDouglas K Owens
VA Palo Alto Health Care System, Palo Alto, Calif, USA
Am J Public Health 97:2173-8. 2007..We sought to determine the prevalence of HIV in both inpatient and outpatient settings in 6 Department of Veterans Affairs (VA) health care sites... - Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysisChrysoula Dosiou
Division of Endocrinology, Department of Medicine, Stanford University Medical Center, 300 Pasteur Drive, S025, Stanford, California 94305, USA
Eur J Endocrinol 158:841-51. 2008..Our objective was to examine the cost-effectiveness of screening pregnant women for autoimmune thyroid disease... 
HIV testing of at risk patients in a large integrated health care systemDouglas K Owens
VA Palo Alto Healthcare System, Palo Alto, CA, USA
J Gen Intern Med 22:315-20. 2007..Understanding HIV screening practices and barriers to HIV testing is an important prelude to designing successful HIV screening programs. Our objective was to evaluate current practice patterns for identification of HIV...- Policy rounds: a new series and a call for papersMark Helfand
Med Decis Making 28:169-71. 2008 - Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testingHenry D Anaya
Center for the Study of Healthcare Provider Behavior, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
J Gen Intern Med 23:800-7. 2008..HIV rapid testing is effective in many healthcare settings, but scant research has been done within primary care settings or within the US Department of Veteran's Affairs Healthcare System... - Decision science and cervical cancerScott B Cantor
Section of Health Services Research, Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:2003-8. 2003..The ultimate objective of using decision-analytic and cost-effectiveness models is to identify ways to improve women's health at an economically reasonable cost... - Cost-effectiveness as an outcome in randomized clinical trialsMark A Hlatky
Stanford University School of Medicine, Stanford, CA 94305 5405, USA
Clin Trials 3:543-51. 2006..Economic outcomes are now included in many contemporary randomized trials and provide an additional dimension to the assessment of interventions. Economic data collection and analysis pose several methodologic challenges, however... - Evidence-based medicine and policy: the case of the implantable cardioverter defibrillatorMark A Hlatky
Stanford University School of Medicine, Stanford, California, USA
Health Aff (Millwood) 24:42-51. 2005.... - Evaluating human papillomavirus vaccination programsAl V Taira
Stanford School of Medicine, Stanford, California, USA
Emerg Infect Dis 10:1915-23. 2004..Vaccination against HPV-16 and HPV-18 can be cost-effective, although including male participants in a vaccination program is generally not cost-effective, compared to female-only vaccination... - Evidence-based practice for mere mortals: the role of informatics and health services researchIda Sim
Division of General Internal Medicine, Department of Medicine and the Graduate Group in Biological and Medical Informatics, University of California San Francisco, 94143 0320, USA
J Gen Intern Med 17:302-8. 2002..We discuss 2 illustrative systems--trial banks and a web-based system to develop and disseminate evidence-based guidelines (alchemist)--and conclude with a research and training agenda...
Research Grants
- COMPUTER BASED GUIDELINES TO PREVENT SUDDEN CARDIAC DEATGILLIAN SANDERS; Fiscal Year: 2002..abstract_text> ..
- Preventing Sudden Cardiac Death: Harnessing the Power of Decision Analysis, BayeGILLIAN SANDERS; Fiscal Year: 2009....
- Preventing Sudden Cardiac Death: Harnessing the Power of Decision Analysis, BayeGillian D Sanders; Fiscal Year: 2010....